BridgeBio falls despite new Attruby data
Source: SeekingAlpha
2026-05-11 15:11:26 ET
More on BridgeBio Pharma
- BridgeBio Pharma, Inc. (BBIO) Q1 2026 Earnings Call Transcript
- BridgeBio: Attruby's Early Dominance Makes The Bull Case Hard To Ignore
- BridgeBio Pharma: Genetic Disease Specialist Is Thriving - I'm Upgrading To Buy
- BridgeBio outlines $500M share repurchase as it targets P&L breakeven in 2027
- BridgeBio Pharma Q1 2026 Earnings Preview
Read the full article on Seeking Alpha
For further details see:
BridgeBio falls despite new Attruby data
BridgeBio Pharma Inc.
NASDAQ: BBIO
BBIO Trading
-1.79% G/L:
$67.57 Last:
495,795 Volume:
$67.97 Open:
BBIO Latest News
May 27, 2026 07:30:00 am
BridgeBio Announces FDA Acceptance and Priority Review of NDA for BBP-418 for LGMD2I/R9
May 12, 2026 07:30:00 am
BridgeBio Submits NDA to FDA for Encaleret for Individuals Living with ADH1
BBIO Stock Data
$13,905,867,946
157,635,809
2.34%
155
N/A
Biotechnology & Life Sciences
Healthcare
US
Palo Alto
